A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model

Archives of Virology

Volumn 155, Issue 6, 2010, Pages 847-856

  Mellado Sánchez, Gabriela ^a,b   García Machorro, Jazmín ^a   Sandoval Montes, Claudia ^b   Gutiérrez Castañeda, Benito ^c   Rojo Domínguez, Arturo ^d   García Cordero, Julio ^a   Santos Argumedo, Leopoldo ^a   Cedillo Barrón, Leticia ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d DEPARTAMENTO DE PROCESOS Y TECNOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DNA VACCINE; E GLYCOPROTEIN, DENGUE VIRUS TYPE 2; E-GLYCOPROTEIN, DENGUE VIRUS TYPE 2; NS1 PROTEIN, DENGUE VIRUS TYPE 2; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; DENGUE; DENGUE VIRUS; DISEASE MODEL; GENETICS; HAMSTER; HUMAN; IMMUNIZATION; IMMUNOLOGY; MOUSE; PLASMID; VACCINATION; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CRICETINAE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINATION; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

ANIMALIA; DENGUE VIRUS; MUS;

EID: 77953362987     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0652-x     Document Type: Article

References (53)

1. Aberle JH, Aberle SW, Allison SL, Stiasny K, Ecker M, Mandl CW, Berger R, Heinz FX (1999) A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J Immunol 163: 6756-6761.
2. An LL, Whitton JL (1997) A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. J Virol 71: 2292-2302.
3. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, Martinez R, Castro J, Santana E, Hermida L, Guillen G, Guzman MG (2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80: 194-199.
4. Cahour A, Falgout B, Lai CJ (1992) Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease. J Virol 66: 1535-1542.
5. Cedillo-Barron L, Foster-Cuevas M, Belsham GJ, Lefevre F, Parkhouse RM (2001) Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol 82: 1713-1724.
6. Chang HH, Shyu HF, Wang YM, Sun DS, Shyu RH, Tang SS, Huang YS (2002) Facilitation of cell adhesion by immobilized dengue viral nonstructural protein 1 (NS1): arginine-glycine-aspartic acid structural mimicry within the dengue viral NS1 antigen. J Infect Dis 186: 743-751.
7. Cheng HJ, Lin CF, Lei HY, Liu HS, Yeh TM, Luo YH, Lin YS (2009) Proteomic analysis of endothelial cell autoantigens recognized by anti-dengue virus nonstructural protein 1 antibodies. Exp Biol Med 234: 63-73.
8. Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, Fremont DH, Diamond MS (2006) Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80: 1340-1351.
9. Chung KM, Thompson BS, Fremont DH, Diamond MS (2007) Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 81: 9551-9555.
10. Costa SM, Azevedo AS, Paes MV, Sarges FS, Freire, Alves AM (2007) DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 358(20): 413-423.
11. Costa SM, Freire MS, Alves AM (2006) DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. Vaccine 24: 4562-4564.
12. Costa SM, Paes MV, Barreto DF, Pinhao AT, Barth OM, Queiroz JL, Armoa GR, Freire MS, Alves AM (2006) Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 24: 195-205.
13. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769-7773.
14. Delenda C, Staropoli I, Frenkiel MP, Cabanie L, Deubel V (1994) Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 75: 1569-1578.
15. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189: 990-1000.
16. Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, Khanna N (2008) An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 79: 353-363.
17. Goncalvez AP, Purcell RH, Lai CJ (2004) Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 78: 12919-12928.
18. Gorrochotegui-Escalante N, Gomez-Machorro C, Lozano-Fuentes S, Fernandez-Salas L, De Lourdes MM, Farfan-Ale JA, Garcia-Rejon J, Beaty BJ, Black WC (2002) Breeding structure of Aedes aegypti populations in Mexico varies by region. Am J Trop Med Hyg 66: 213-222.
19. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10: 100-103.
20. Guzman MG, Kouri G (2002) Dengue: an update. Lancet Infect Dis 2: 33-42.
21. Guzman MG, Rodriguez R, Rodriguez R, Hermida L, Alvarez M, Lazo L, Mune M, Rosario D, Valdes K, Vazquez S, Martinez R, Serrano T, Paez J, Espinosa R, Pumariega T, Guillen G (2003) Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 69: 129-134.
22. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra BL, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24: 3165-3171.
23. Hurtado-Diaz M, Riojas-Rodriguez H, Rothenberg SJ, Gomez-Dantes H, Cifuentes E (2007) Short communication: impact of climate variability on the incidence of dengue in Mexico. Trop Med Int Health 12: 1327-1337.
24. Katrak K, Mahon BP, Jones WC, Brautigam S, Mills KH (1992) Preparative separation of foreign antigens for highly efficient presentation to T cells in vitro. J Immunol Methods 156: 247-254.
25. Kelly EP, Greene JJ, King AD, Innis BL (2000) Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18: 2549-2559.
26. Khanam S, Khanna N, Swaminathan S (2006) Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24: 6513-6525.
27. Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, Porter K, Hayes C (1997) Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15: 547-552.
28. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
29. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV (1992) Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 30: 545-551.
30. Lazaro-Olan L, Mellado-Sanchez G, Garcia-Cordero J, Escobar-Gutierrez A, Santos-Argumedo L, Gutierrez-Castaneda B, Cedillo-Barron L (2008) Analysis of antibody response in human dengue patients from the Mexican coast using recombinant antigens. Vector Borne Zoonotic Dis 8: 69-80.
31. Lazo L, Zulueta A, Hermida L, Blanco A, Sanchez J, Valdes I, Gil L, Lopez C, Romero Y, Guzman MG, Guillen G (2008) The Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 52 (Pt): 265-271.
32. Limon-Flores AY, Perez-Tapia M, Estrada-Garcia I, Vaughan G, Escobar-Gutierrez A, Calderon-Amador J, Herrera-Rodriguez SE, Brizuela-Garcia A, Heras-Chavarria M, Flores-Langarica A, Cedillo-Barron L, Flores-Romo L (2005) Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. Int J Exp Pathol 86: 323-334.
33. Mason PW, Zugel MU, Semproni AR, Fournier MJ, Mason TL (1990) The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli. J Gen Virol 71: 2107-2114.
34. Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, van Regenmortel MH, Deubel V (1992) Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187: 480-491.
35. Mellado-Sanchez G, Garcia-Cordero J, Luria-Perez R, Lazaro-Olan L, Santos-Argumedo L, Gutierrez-Castaneda B, Estrada-Garcia I, Cedillo-Barron L (2005) DNA priming E and NS1 constructs-homologous proteins boosting immunization strategy to improve immune response against dengue in mice. Viral Immunol 18: 709-721.
36. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100: 6986-6991.
37. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79: 1223-1231.
38. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22: 250-254.
39. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81: 11828-11839.
40. Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG (1998) Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 143: 997-1003.
41. Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, Ing E, Dubois D, Sparkuhl J, Gastle W, Hoke C (1996) Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 55: 504-510.
42. Putnak R, Feighny R, Burrous J, Cochran M, Hackett C, Smith G, Hoke C (1991) Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 45: 159-167.
43. Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW (2003) Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg 68: 469-476.
44. Roehrig JT (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141-175.
45. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317-328.
46. Schlesinger JJ, Brandriss MW, Walsh EE (1987) Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 68: 853-857.
47. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R (2006) Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80: 9577-9585.
48. Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr (1995) Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13: 1251-1258.
49. Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP (2006) Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 193: 1658-1665.
50. Timofeev AV, Butenko VM, Stephenson JR (2004) Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes 28: 85-97.
51. Vasquez-Ochoa M, Garcia-Cordero J, Gutierrez-Castaneda B, Santos-Argumedo L, Villegas-Sepulveda N, Cedillo-Barron L (2009) A clinical isolate of dengue virus and its proteins induce apoptosis in HMEC-1 cells: a possible implication in pathogenesis. Arch Virol 154: 919-928.
52. Wei HY, Jiang LF, Xue YH, Fang DY, Guo HY (2003) Secreted expression of dengue virus type 2 full-length envelope glycoprotein in Pichia pastoris. J Virol Methods 109: 17-23.
53. Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK (2003) Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21: 3919-3929.